Enochian BioSciences

About:

Enochian BioSciences is focusing on the clinical development of a dendritic cell vaccine for treatment of colorectal cancer.

Website: http://www.enochianbio.com/

Twitter/X: enochian_biosci

Description:

Enochian BioSciences is a biotechnology company focusing on VIVA, a Phase III clinical trial for our lead candidate MCV. MCV is an adjuvant immunotherapy that is designed to prevent colon cancer recurrence after standard of care surgery and chemotherapy. MCV, a dendritic cell cancer vaccine, can be used in several solid tumors either as a standalone adjuvant therapy or in combination with checkpoint inhibitors. Our expertise in producing dendritic cells from a patient's blood is combined with conventional production methods with a goal of making new and advanced vaccines for cancer patients.

Total Funding Amount:

$155M

Headquarters Location:

New York, New York, United States

Founded Date:

2011-01-01

Founders:

Rene Sindlev

Number of Employees:

11-50

Last Funding Date:

2024-02-13

IPO Status:

Public

Industries:

© 2025 bioDAO.ai